IMPAACT P1089 (VERSION 10) A LABORATORY STUDY TO ASSESS THE IMMUNOGENICITY

IMPAACT P1089（版本 10）评估免疫原性的实验室研究

• 批准号: 8356738
• 负责人: William Thomas Shearer
• 金额: $ 0.18万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-12-01 至 2011-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8356738
• 关键词: Address; Adult; Age-Years; Cessation of life; Child; Clinical Research; Communities; Data; Disease; Elderly; Epidemic; Funding; Grant; HIV-1; Healthcare; IMPAACT; Immune response; Immunologic Deficiency Syndromes; Individual; Influenza; Influenza A Virus, H1N1 Subtype; Influenza A virus; Knowledge; Laboratory Study; Licensing; Measurable; Measures; Medical; National Center for Research Resources; Population; Predisposition; Principal Investigator; Puerto Rico; Relative (related person); Reporting; Research; Research Infrastructure; Resources; Risk; ST14 gene; Seasons; Serological; Serum; Severity of illness; Social Interaction; Source; United States National Institutes of Health; Vaccines; Virus; Virus Diseases; Vulnerable Populations; cost; falls; high risk; immunogenicity; influenzavirus; neutralizing antibody; pandemic disease; seasonal influenza; young adult

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. It is very likely that the continuing epidemic spread of 2009 H1N1 Influenza A virus infection in the US will greatly increase in the fall-winter season when social interactions and climactic conditions become even more conducive to spread of influenza viruses. While reports to date suggest that healthy individuals typically have a mild illness, underlying medical conditions including immunodeficiency appear to increase risk for severe disease and even death with pandemic H1N1. Thus, knowledge of the immunogenicity of several of the licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-1 perinatally infected children and youth is critically important to address the health care needs of this vulnerable population. It is well established that seasonal influenza infection impacts children in a community before becoming widespread in adult populations. Susceptibility to disease among young populations appears even more pronounced with 2009 H1N1 Influenza A virus as one third of older adults have measurable levels of serum HAI or neutralizing antibody against the 2009 H1N1 Influenza A virus while young adults and children completely lack protective titers. The serologic data is consistent with the observation that the attack rate and disease severity for the virus appears to be much higher in younger populations with relative protection of those 50 years of age. Efforts are currently underway to evaluate Influenza A (H1N1) 2009 monovalent vaccines in healthy children as well as other populations. Protection of HIV-1 perinatally infected children and youth from 2009 H1N1 Influenza A virus will require knowledge of immunogenicity of these new licensed products in this population. This study, P1089, will assess the immune response following receipt of licensed Influenza A (H1N1) 2009 monovalent vaccines in HIV-1 perinatally infected children and youth in the US and Puerto Rico. In order to understand the mechanism of disease and protection, we will investigate the short term seroresponse in this population. In summary, 2009 H1N1 Influenza A virus is likely to infect a significant proportion of HIV-1 perinatally infected children and youth. Immunogenicity of licensed available Influenza A (H1N1) 2009 monovalent vaccines must be established in HIV-1 perinatally infected children in order to assure that this population is protected. Lack of a protective immune response would support the need for additional measures to protect this high risk population.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 很有可能，2009年H1N1甲型流感病毒感染在美国的持续疫情传播将在秋冬季大幅增加，届时社会互动和气候条件变得更加有利于流感病毒的传播。虽然到目前为止的报告表明，健康的人通常患有轻微的疾病，但包括免疫缺陷在内的潜在医疗状况似乎增加了患严重疾病甚至死于甲型H1N1大流行的风险。因此，了解几种获得许可的2009年甲型H1N1流感单价疫苗在围产期感染艾滋病毒-1的儿童和青年中的免疫原性对于满足这一弱势群体的卫生保健需求至关重要。 众所周知，季节性流感感染会先影响社区中的儿童，然后才会在成人中传播。年轻人对疾病的易感性在2009年H1N1甲型流感病毒中表现得更加明显，因为三分之一的老年人有可测量的血清HAI或2009年H1N1甲型流感病毒的中和抗体水平，而年轻人和儿童完全缺乏保护性滴度。血清学数据与观察到的情况一致，即在相对保护50岁的年轻人群中，病毒的发病率和疾病严重程度似乎要高得多。 目前正在努力评估2009年甲型H1N1流感单价疫苗在健康儿童和其他人群中的应用。要保护围产期感染艾滋病毒-1的儿童和青年免受2009年H1N1甲型流感病毒感染，将需要了解这些新的特许产品在这一人群中的免疫原性。 这项名为P1089的研究将评估在美国和波多黎各接种获得许可的2009年甲型H1N1流感单价疫苗后，美国和波多黎各围产期感染艾滋病毒-1的儿童和青少年的免疫反应。 为了了解疾病和保护的机制，我们将调查该人群的短期血清反应。 总而言之，2009年H1N1甲型流感病毒很可能感染围产期感染艾滋病毒-1的儿童和青少年的相当大比例。必须在围产期感染艾滋病毒-1的儿童中确定获得许可的2009年甲型H1N1流感单价疫苗的免疫原性，以确保这一人群得到保护。缺乏保护性免疫反应将支持采取额外措施保护这一高危人群的必要性。